FASEB Offers Recommendations to Improve Research Funding

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Federation of American Societies for Experimental Biology called for a re-examination of the way research is funded in the U.S., in a report detailing the challenges facing researchers and the threats to continued progress in the field.

The report, Sustaining Discovery in Biological and Medical Science: A Framework for Discussion, presents a series of recommendations to alleviate them.

Shortfalls in federal funding and rising regulatory costs have constrained research budgets, while at the same time, scientific opportunities have expanded and more individuals are seeking funding, the report says. These opposing trends have resulted in an increasingly unstable research enterprise, delaying scientific discovery.

FASEB’s recommendations fall into three categories:

  • Increased advocacy for predictable, sustainable growth in research budgets while striving to make optimal use of existing resources
  • Re-examination of the way research is funded, making certain that we provide incentives to encourage the best science and reduce the amount of time spent seeking funding, and
  • Improved preparation and utilization of the workforce.

“After adjusting for inflation, the federal investment in the life science has declined by more than 20 percent since 2003,” the report says. “Insufficient funding—along with increased regulatory burden and budgetary uncertainty—is a growing obstacle to future advancement.” FASEB recommends that, due to this budget uncertainty, federal research agencies should be able to carry over their budgets into the following fiscal year.

The organization also called for a reduction of the time spent preparing and reviewing grant applications, and that sponsors should consider extending the duration of investigator-initiated awards to decrease the amount of effort spent on competing for funding.

The report is available on FASEB’s website.

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login